New
Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Advertisement
Advertisement
CRCAvsETF 2ETF Comparison
ETF 2
Choose a second ETF to run a side-by-side ETF comparison with CRCA, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
CRCA performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 03/12/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CRCA ETF 2 | +255.21%– | +41.90%– | +63.51%– | n/a– | n/a– | n/a– |
| Flows | CRCA ETF 2 | -$78M– | -$40M– | -$64M– | -– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CRCA ETF 2 | +217.56%– | n/a– | n/a– | n/a– |
| Max drawdown | CRCA ETF 2 | -69.44%– | n/a– | n/a– | n/a– |
| Max drawdown duration | CRCA ETF 2 | 70d– | n/a– | n/a– | n/a– |
Trading data
CRCA | ETF 2 | |
Last sale | – | |
| Previous close 03/12/2026 | – | |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Replication data will be available soon
Advertisement
Main metrics
CRCA | ETF 2 | |
|---|---|---|
| Last price | – | – |
| 1D performance | – | – |
| AuM | $211.90 M | – |
| E/R | 1.08% | – |
Characteristics
CRCA | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | ProShares | – |
| Benchmark | CRCL Price | – |
| N° of holdings | - | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 6, 2025 | – |
| ESG | No | – |
Advertisement
Exposure
Exposure data will be available soon
Advertisement
Latest news about CRCA
Advertisement
Advertisement
Webcast on Demand
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
